RenovoRx Announces $10 Million Financing for Innovative Treatment for Advanced Pancreatic Cancer
RenovoRx, Inc., a medical technology company developing an innovative catheter-based approach to treating pancreatic cancer, today announced a $10 million financing round of which the company closed $7 million in an initial tranche. The round is led by Boston Scientific and joined by new investors including btov Partners and existing investors Astia Angels, the Angels’ Forum, the Halo Fund III, L.P., Golden Seeds, and Acorn Campus Taiwan.
RenovoRx Announces $10 Million Financing for Innovative Treatment for Advanced Pancreatic Cancer
RenovoRx today announced a $10 million financing round of which the company closed $7 million in an initial tranche. The round is led by Boston Scientific and joined by new investors including btov Partners and existing investors Astia Angels, the Angels’ Forum, the Halo Fund III, L.P., Golden Seeds, and Acorn Campus Taiwan.